Component
New mood-episode intervention in the BALANCE trial
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Lithium monotherapy had fewer new mood-episode interventions than valproate in BALANCE; adding valproate was not clearly superior to lithium alone.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- 330 randomized bipolar-I patients; open-label treatment with masked event review; up to two years.
- limitations
- Combination run-in and open-label design matter; the trial does not identify a single molecular mediator.
- nutrient_topic
- Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
- plain_language
- Clinical mood efficacy has its own evidence, separate from dementia hypotheses.
- primary_references
- Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20092882/ · DOI 10.1016/S0140-6736(09)61828-6
Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 560–566
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · 330 randomized bipolar-I patients; open-label treatment with masked event review; up to two years. · source_derived_draft · unverified_draft
## lithium-bipolar-relapse Clinical mood efficacy has its own evidence, separate from dementia hypotheses. Lithium monotherapy had fewer new mood-episode interventions than valproate in BALANCE; adding valproate was not clearly superior to lithium alone. Model: 330 randomized bipolar-I patients; open-label treatment with masked event review; up to two years. Limitations: Combination run-in and open-label design matter; the trial does not identify a single molecular mediator. Evidence access: Primary abstract Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20092882/ · DOI 10.1016/S0140-6736(09)61828-6
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.